☰

Debra A. Tonetti

Affiliations: 
University of Illinois at Chicago, Health Sciences Center, Chicago, IL 60612, United States 
Area:
Pharmacy, Pharmacology, Cell Biology, Oncology
Google:
"Debra Tonetti"
Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor

Children

Sign in to add trainee
Jieun Yun grad student 2007 University of Illinois at Chicago, Health Sciences Center

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Shete N, Calabrese J, Tonetti DA. (2023) Revisiting Estrogen for the Treatment of Endocrine-Resistant Breast Cancer: Novel Therapeutic Approaches. Cancers. 15
Pal P, Millner A, Semina SE, et al. (2022) Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells. Cancers. 14
Means-Powell JA, Mayer IA, Ismail-Khan R, et al. (2021) A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC). Clinical Breast Cancer. 22: 103-114
Abderrahman B, Maximov PY, Curpan RF, et al. (2020) Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics
Abderrahman B, Maximov PY, Curpan RF, et al. (2020) Pharmacology and Molecular Mechanisms of Clinically-Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for Endocrine-Resistant Breast Cancer Treatment. Molecular Pharmacology
Dudek AZ, Liu LC, Fischer JH, et al. (2020) Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. Breast Cancer Research and Treatment
Li Y, Zhao J, Gutgesell L, et al. (2020) Novel pyrrolopyridone bromodomain and extra-terminal motif (BET) inhibitors effective in endocrine-resistant ER+ breast cancer with acquired resistance to fulvestrant and palbociclib. Journal of Medicinal Chemistry
Andreano KJ, Wardell SE, Baker JG, et al. (2020) G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment
O'Regan R, Hurley R, Sachdev J, et al. (2020) Abstract P5-11-06: Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine therapy Cancer Research. 80
Lu Y, Gutgesell L, Xiong R, et al. (2019) Design and Synthesis of Basic Selective Estrogen Receptor Degraders (B-SERDs) for Endocrine Therapy Resistant Breast Cancer. Journal of Medicinal Chemistry
See more...